Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

141.25GBp
6:42pm IST
Price Change (% chg)

0.75p (+0.53%)
Prev Close
140.50p
Open
139.50p
Day's High
142.00p
Day's Low
138.50p
Volume
74,899
Avg. Vol
823,207
52-wk High
171.50p
52-wk Low
92.49p

VEC.L

Chart for VEC.L

About

Vectura Group plc (Vectura) is a developer of therapies principally for the treatment of respiratory diseases. The Company is engaged in developing treatments for respiratory diseases. Vectura’s products target diseases, such as asthma and chronic obstructive pulmonary disease (COPD). The Company’s pharmaceutical business... (more)

Overall

Beta: -0.15
Market Cap (Mil.): £564.34
Shares Outstanding (Mil.): 401.66
Dividend: --
Yield (%): --

Financials

  VEC.L Industry Sector
P/E (TTM): -- 35.82 36.29
EPS (TTM): -0.01 -- --
ROI: -1.08 18.85 18.13
ROE: -1.27 19.57 18.95
Search Stocks

BRIEF-Vectura says in US collaboration agreement for VR506 asthma therapy

* Announces a further US collaboration agreement with a leading international pharmaceutical company for VR506 asthma therapy

30 Jun 2014

UPDATE 2-Vectura revenue jumps on royalty push, sees more growth

* Shares rise as much as 3.5 pct (Adds CEO and analyst comments; updates share movement)

21 May 2014

Vectura revenue rises 20 pct on higher royalty payments

May 21 - Drug developer Vectura Group Plc reported a 20 percent rise in full-year revenue as it benefited from higher royalty payments for drugs it has licensed.

21 May 2014

BRIEF-Vectura Group revenue rises 20 pct

* FY revenue rises 20 percent to 36.5 million stg (2012/13: 30.5 million stg)

21 May 2014

BRIEF-Vectura to initiate study for asthama medicine Favolir in Europe

* Will initiate a pivotal study in Europe later this calendar year for Favolir, its investigational product for severe, uncontrolled asthma

11 Apr 2014

BRIEF-Vectura gets $3 mln milestone for VR315 progress in US

March 25 - Vectura Group PLC : * Gets $3 million milestone associated with the development of VR315 in the US * VR315 is generic copy of GlaxoSmithKline's $8 billion-a-year inhaled lung drug Advair * Source text for Eikon: * For more news, please click here

25 Mar 2014

BRIEF- Vectura raises about 52 mln stg through placing

March 13 - Vectura Group PLC : * Placing of approximately 33.6 million new ordinary shares, raised approximately £52.0 million * Placed by Peel Hunt LLP , J.P. Morgan Securities Plc at a price of 155 pence per placing share * Placing shares being issued represent about 9.9 percent of the issued ordinary share capital of Vectura prior to the placing * Intends to use the net proceeds to progress the development of Favolir and launch and/or partner Favolir in the EU and US markets

13 Mar 2014

BRIEF-Vectura says partner Sandoz receives Belgian approval for Airflusal Forspiro

Feb 12 - Vectura Group PLC : * Belgian regulatory authority confirm approval of airflusal forspiro * Partner sandoz has received Belgian marketing authorisation for Airflusal Forspiro for patients with asthma, copd * Receipt of the Belgian marketing authorisation by sandoz triggers a milestone payment to Vectura of E1.5 million * Source text for Eikon: * For more news, please click here

12 Feb 2014

BRIEF-Vectura receives Norwegian approval for Airflusal Forspiro

Feb 10 - Vectura Group PLC : * Norwegian regulatory authority confirm approval of airflusal forspiro * Treatment is new inhaler for patients with asthma and chronic obstructive

10 Feb 2014

Earnings vs. Estimates

Search Stocks